As discussed at the review, some safety issues remain to be clarified in post-marketing. These include the long-term safety effects of liver function, hematologic, and lipid abnormalities, as well as the occurrence of gastrointestinal perforation, which, though a rare, was observed more often in tocilizumab treated patients compared to those who received placebo.
Founded in 1998, the Arthritis Center at Johns Hopkins is dedicated to providing quality education to patients and healthcare providers alike.
Use of this Site
All information contained within the Johns Hopkins Arthritis Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.